Physician profile
John T Bender
NPI 1528032448
$3,694.01
in general payments reported to CMS, 2019-2025
13 companies · $754 in 2025
The $754 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $229 · 2021: $343 · 2022: $723 · 2023: $872 · 2024: $560 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,016 · Entertainment: $164 · Education: $4.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,016.41 |
| Entertainment | $163.93 |
| Education | $4.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,133.67 | 2019-2025 | Total30, Precision 1, Dailies Total1 |
| Abbvie INC. | $277.57 | 2022-2025 | |
| Allergan, INC. | $257.79 | 2020-2022 | |
| Optos, INC. | $203.15 | 2020-2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Bausch & Lomb Americas INC. | $178.29 | 2022-2025 | Miebo, Xiidra |
| Carl Zeiss Meditec USA, INC. | $140.20 | 2021-2024 | Clarus, Cirrus Hd-Oct |
| Astellas Pharma US INC | $125.00 | 2023 | |
| Shire North American Group INC | $106.01 | 2019 | |
| Glaukos Corporation | $101.70 | 2024 | Ce-Marked Kxla System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $72.14 | 2020-2021 | |
| Dompe US, INC. | $40.92 | 2024 | Oxervate |
| Oyster Point Pharma, INC. | $40.13 | 2023 | Tyrvaya |
| Coopervision INC. | $17.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.